• Publications
  • Influence
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
TLDR
The disease definition of multiple myeloma is updated to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions), and specific metrics that new biomarkers should meet for inclusion in the disease definition are provided.
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
TLDR
It is concluded that V617F is widespread in MPDs and detection of this acquired mutation is likely to have a major impact on the way patients with MPD are diagnosed, as well as serving as an obvious target for signal transduction therapy.
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
TLDR
Several aspects of disease response assessment are clarified, along with endpoints for clinical trials, and future directions for disease response assessments are highlighted, to allow uniform reporting within and outside clinical trials.
Hematological findings and complications of COVID‐19
TLDR
COVID‐19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended.
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma
TLDR
Bone scintigraphy has no place in the routine staging of myeloma, whereas sequential dual-energy X-ray absorptiometry scans are not recommended, and Positron emission tomography/CT or MIBI imaging are also not recommended for routine use in the management of Myeloma patients.
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
TLDR
The risk of ONJ is increased with time of exposure and probably with the use of zoledronic acid.
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
TLDR
The results highlight the beneficial effect of HU, which seems to modify the natural history of SCD and raise the issue of expanding its use in all SCD patients.
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
TLDR
BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw, and ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits.
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
TLDR
The risk of developing Osteonecrosis of the jaw after treatment of zoledronic acid is reduced (but not deleted) by the implementation of preventive measures.
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.
TLDR
MRI at diagnosis of symptomatic patients and after treatment (mainly after autologous stem-cell transplantation) provides prognostic information; however, to date, this does not change treatment selection.
...
1
2
3
4
5
...